Michael Dial

Experienced investor, company builder and scientist. Mike has over 15 years of experience working with early-stage life science and healthcare companies. Mike joined Hatteras in 2009 from Silicon Valley Bank, where he was a Vice President in the Corporate Finance Group focused on emerging tech and life science companies and venture capital funds. Prior to SVB, he held research scientist positions in the Department of Biochemistry at UNC-Chapel Hill, the Laboratory of Structural Biology at the National Institute of Environmental Health Sciences, and the UNC-Duke Michael Hooker Proteomics Center. He has performed research in the fields of cell cycle regulation, proteomics, and cancer therapy.

Mike has been a Professor of the Practice at the Kenan-Flagler Business School since 2017 and is the Manager for L2 Ventures, a fund dedicated to UNC-Chapel Hill related start-ups. He holds a Ph.D. in Biochemistry and Biophysics from UNC-Chapel Hill.

Mike serves on the boards of Ribometrix and Atsena Therapeutics and is an observer for StrideBio. Previously, Mike was involved with G1 Therapeutics, Viamet, Lysosomal Therapeutics, and Artizan Biosciences, among others, and has held various operational roles in Hatteras portfolio companies. Mike has also served on various committees and panels for the North Carolina Biotech Center, Council for Entrepreneurial Development, SEBIO and PTP NEXT and currently serves on the board of Southeast Life Sciences.

Companies

• Professor of the Practice UNC Kenan-Flagler Business School (2017)
• Fund Manager Carolina Research Ventures Fund (2016)
• General Partner Hatteras Venture Partners (2009)
• VP and Relationship Manager SVB Financial Group (2007 — 2009)
• Laboratory Research Specialist UNC-Duke Michael Hooker Proteomics Facility (2001 — 2002)
• Research Chemist National Institute of Environmental Health Sciences (2000 — 2001)

Education

• PhD University of North Carolina at Chapel Hill School of Medicine (2002.08 — 2007.05)